Form 4: Aldeyra Therapeutics Director, William D. Clark, Acquires Stock Options

Director William D. Clark acquired stock options in Aldeyra Therapeutics, Inc. exercisable over three years.

Summary

• William D. Clark, a director of Aldeyra Therapeutics, Inc., acquired stock options on April 17, 2025.
• The options grant the right to buy 76,760 shares of common stock at an exercise price of $2.19 per share.
• The stock options vest in equal annual installments over three years of continuous service to the Issuer after April 17, 2025.
• The expiration date for the options is April 16, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director. While insider ownership can be a positive signal, this is a routine grant.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's increased stake in the company, which is common practice.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholders, as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, director, ALDX, Aldeyra Therapeutics, Form 4, beneficial ownership, securities